Status:
COMPLETED
Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Coinfection With Hepatitis B Virus and Hepatitis C Virus
Monoinfection With Hepatitis C Virus
Eligibility:
All Genders
18+ years
Brief Summary
Chronic hepatitis C may relapse in simple chronic hepatitis C patients who initially obtained sustained virologic responses. Although the HCV SVR could be maintained in around 90%, the remaining 10% o...
Detailed Description
Pegylated IFNs (such as PEG-IFN alfa-2a, PEGASYS®) have been shown to possess a superior efficacy and convenience to conventional IFNs, either alone or in combination with RBV in patients with chronic...
Eligibility Criteria
Inclusion
- Patients who were randomized, treated and returned for follow up in the ML17862 protocol will be eligible for inclusion in this protocol
Exclusion
- Patients unwilling to provide informed consent or abide by the requirements of the study.
- Patients who have already initiated anti-HCV or HBV treatment, approved or investigational since completion of the original protocol
Key Trial Info
Start Date :
May 1 2006
Trial Type :
OBSERVATIONAL
End Date :
December 1 2011
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT00361179
Start Date
May 1 2006
End Date
December 1 2011
Last Update
August 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pei-Jer Chen
Taipei City, Taiwan, China, 100